Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients

Molecular Diagnosis and Therapy

Volumn 18, Issue 5, 2014, Pages 559-566

  Roszkowski, Krzysztof ^a,b   Zurawski, Bogdan ^a   Jozwicki, Wojciech ^b   Basta, Pawel ^a,c   Lewandowska, Marzena Anna ^a,b  

^a Centrum Onkologii im prof F Lukaszczyka w Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; COLORECTAL NEOPLASMS; EXON; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; MUTATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RADIOTHERAPY, ADJUVANT; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84933037024     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0107-2     Document Type: Article

References (18)

1. O’Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937–44.
2. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–6.
3. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101(4):715–21.
4. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19(7):1902–12.
5. Lewandowska MA, Jozwicki W, Zurawski B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther. 2013;17(3):193–203.
6. Lewandowska MA, Jozwicki W, Jochymski C, Kowalewski J. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncol Rep. 2013;30(3):1045–52.
7. Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, et al. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: clinical outcome and biomarkers of efficacy. Cancer Biol Ther. 2013;14(12):1098–103.
8. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.
9. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol/Hematol. 2013;85(1):45–81.
10. Bazan V, Agnese V, Corsale S, Calo V, Valerio MR, Latteri MA, et al. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol. 2005;16 Suppl 4:iv50–5.
11. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.
12. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20.
13. Kirk R. Genetics: in colorectal cancer, not all KRAS mutations are created equal. Nat Rev Clin Oncol. 2011;8(1):1.
14. Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer. 2012;78(1):81–6.
15. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature. 1984;312(5989):71–5.
16. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27.
17. Cho WC. Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev Mol Diagn. 2011;11(7):691–4.
18. Fadhil W, Kindle K, Jackson D, Zaitoun A, Lane N, Robins A, et al. DNA content analysis of colorectal cancer defines a distinct ‘microsatellite and chromosome stable’ group but does not predict response to radiotherapy. Int J Exp Pathol. 2014;95(1):16–23.